Reconstructing the skeleton with intermittent parathyroid hormone

Trends in Endocrinology and Metabolism

Volumn 12, Issue 7, 2001, Pages 281-283

  Seeman, Ego ^a   Delmas, Pierre D ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE;

ANIMAL; BONE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; FRACTURE; HUMAN; INJURY; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANIMALS; BONE AND BONES; BONE RESORPTION; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; RANDOMIZED CONTROLLED TRIALS;

EID: 0035461379     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(01)00460-X     Document Type: Review

References (17)

1. Neer, R.M. et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl. J. Med 344, 1434-1441
2. Cosman, F. et al. (2001) Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J. Bone Miner. Res. 16, 925-931
3. Kneissel, M. et al. (2001) Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone 28, 237-250
4. Li, M. and Wronski, TJ. (1995) Response of femoral neck to estrogen depletion and parathyroid hormone in aged rats. Bone 16, 551-557
5. Thomsen, J.S. et al. (1999) Long-term therapy of ovariectomy-induced osteopenia with parathyroid hormone analog SDZPTS 893 and bone maintenance in retired breeder rats. Bone 25, 561-569
6. Sato, M. et al. (1997) Biosynthetichuman parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats. Endocrinology 138, 4330-4337
7. Hirano, T. et al. (1999) Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J. Bone Miner. Res. 14, 536-545
8. Jerome, C.P. et al. (2001) Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28, 150-159
9. Lane, N.E. et al. (1995) Intermittent treatment with human parathyroid hormone (hPTH[1-34]) increased trabecular bone volume but not connectivity in osteopenic rats. J. Bone Miner. Res. 10, 1470-1477
10. Qi, H. et al. (1995) A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats. J. Bone Miner. Res. 10, 948-955
11. Ejersted, C. et al. (1995) Parathyroid hormone(1-34) increases vertebral bone mass, compressive strength, and quality in old rats. Bone 17, 507-511
12. Parisien, M. et al. (1992) Maintenance of cancellous bone connectivity in primary hyperparathyroidism; trabecular strut analysis. J. Bone Miner. Res. 7, 913-919
13. Burr, D.B. et al. (2001) Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J. Bone Miner. Res. 16, 157-165
14. Gasser, J.A. et al. (2000) PTH and interactions with bisphosphonates. J. Musculoskel. Neuron Interact. 1, 53-56
15. Li, M. et al. (1995) Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats. Bone 16, 629-635
16. Hodsman, A.B. et al. (1997) A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 82, 620-628
17. Delmas, P.D. et al. (1995) The anabolic effect of human PTH(1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate. Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 6, 603-610